The letter’s authors, Chairwoman Willa Field and CEO H. Steven Lieber, called upon the officials to “give a strong message to the industry that ICD-10 has already been thoroughly vetted” and that further delay will be detrimental to hospitals and other providers that have begun implementation.
“By all accounts, further delay in implementing ICD-10 will result in billions of dollars in lost investment for those who have been preparing for ICD-10 nationwide implementation, and the eventual upgrading of the nation’s medical coding standard will cost billions of dollars more the longer we wait,” the authors wrote.
Opponents of ICD-10, such as the American Medical Association, have said the shift and infrastructure of ICD-10 will be a financial and administrative burden.
More Articles on ICD-10:
Clinical Documentation Improvement: What Executives Need to Know and the Financial Impact of Neglect
Evaluate ICD-10 Transition Plans to Account for Payors, Vendors
Providers Should Plan for Unforeseen Costs of ICD-10
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
